STOCK TITAN

Connect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business Update

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Connect Biopharma (CNTB) reported third-quarter financial results and preliminary Phase 2 results for rademikibart in acute asthma and COPD exacerbations. Third-quarter net loss narrowed to $16.150 million from $17.200 million a year earlier, while nine-month net loss widened to $52.832 million from $40.371 million. Cash, cash equivalents and short-term investments fell to $19.493 million at September 30, 2026, from $44.342 million at December 31, 2025.

In asthma, lung function improved significantly, but the overall treatment-failure endpoint missed statistical significance. In COPD, treatment failures fell 81% versus placebo through Week 4, while the lung-function difference was not statistically significant. Neither study identified new safety signals. The company plans FDA discussions on potential Phase 3 programs for asthma in December 2026 and COPD in the first quarter of 2027.

Loading...
Loading translation...
17 points · 2 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 10 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointCOPD treatment failures fell 81% versus placebo through Week 4 in preliminary Phase 2 results (p=0.0122).
  • Major point. Forward-looking: it has not happened yet and may not happen.Simcere agreement offers remaining milestones of up to approximately $99 million, conditional on development, regulatory and commercial achievements. 2.3× market cap
  • Moderate pointAsthma lung-function gains at Day 7 were 250 mL versus 120 mL with placebo (p=0.023), maintained through Week 4 (p=0.012).
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Connect plans FDA discussions on potential Phase 3 programs: December 2026 for asthma and first quarter 2027 for COPD.
  • Minor pointCOPD new moderate-to-severe exacerbations fell 85% versus placebo through Week 4 (p=0.0301).
12 minor points
  • Minor pointCOPD emergency visits and hospital admissions for new exacerbations fell 100% versus placebo through Week 4 (p=0.0137).
  • Minor pointAsthma emergency department or unscheduled medical visits for worsening symptoms fell 50% versus placebo.
  • Minor pointAsthma subgroup meeting proposed Phase 3 entry criteria showed an 86% treatment-failure reduction (p=0.0282).
  • Minor pointBoth Phase 2 studies showed no new safety signals and fewer treatment-emergent and serious adverse events than placebo.
  • Minor pointCOPD symptoms and rescue inhaler use showed statistically significant reductions.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Connect plans to pursue acute and chronic administration of rademikibart for asthma and COPD.
  • Minor pointThird-quarter license and collaboration revenue rose to $736,000 from $16,000 a year earlier.
  • Minor pointNine-month license and collaboration revenue rose to $3.673 million from $64,000 a year earlier.
  • Minor pointThird-quarter administrative expense fell to $4.259 million from $6.583 million a year earlier.
  • Minor pointNine-month administrative expense fell to $13.104 million from $16.096 million a year earlier.
  • Minor pointThird-quarter net loss narrowed to $16.150 million, or $0.26 per share, from $17.200 million, or $0.31.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Simcere agreement provides eligibility for tiered royalties up to low double-digit percentages on Greater China net sales.

Negative

  • Major pointAsthma treatment failures fell approximately 66% over 28 days, but missed statistical significance versus placebo (p=0.153).
  • Moderate pointCash, cash equivalents and short-term investments fell to $19.493 million from $44.342 million at December 31, 2025.
  • Moderate pointNine-month net loss widened to $52.832 million, or $0.87 per share, from $40.371 million, or $0.73.
  • Moderate pointNine-month research and development expense rose to $44.092 million from $26.516 million a year earlier.
  • Moderate pointShareholders' equity fell to $12.055 million from $41.980 million at December 31, 2025.
5 minor points
  • Minor pointCOPD lung-function improvement of 70 mL versus placebo at Week 4 was not statistically significant (p=0.1607).
  • Minor pointThird-quarter research and development expense rose to $12.789 million from $11.110 million a year earlier.
  • Minor pointThird-quarter total other income, net, fell to $182,000 from $538,000 a year earlier.
  • Minor pointNine-month total other income, net, fell to $819,000 from $2.347 million a year earlier.
  • Minor pointTotal assets fell to $27.770 million from $56.075 million at December 31, 2025.

News Explained

In asthma, the treatment-failure reduction was statistically significant under proposed Phase 3 entry criteria, while the overall Phase 2 endpoint was not.

Connect reports its Phase 2 studies are complete and remains eligible under its existing Simcere license for up to $99 million in additional milestones, payable upon development, regulatory or commercial achievements, plus tiered royalties on Greater China net sales.

For asthma, the company reports an 86% treatment-failure reduction using proposed Phase 3 entry criteria that include baseline FEV1 below 80% predicted; the overall Phase 2 treatment-failure endpoint missed statistical significance.

Key Figures

Asthma FEV1 improvement: 250 mL vs. 120 mL; p=0.023; Week 4 p=0.012 Asthma treatment failure reduction: Approximately 66%; p=0.153 Asthma treatment failure reduction: 86%; p=0.0282 +5 more
Asthma FEV1 improvement
250 mL vs. 120 mL; p=0.023; Week 4 p=0.012
Post-bronchodilator lung function at Day 7; improvement maintained through Week 4
Asthma treatment failure reduction
Approximately 66%; p=0.153
Compared with placebo over 28 days; endpoint missed statistical significance
Asthma treatment failure reduction
86%; p=0.0282
Observed using proposed Phase 3 entry criteria, including baseline percent predicted FEV1 <80%
COPD treatment failure reduction
81%; p=0.0122
Compared with placebo through Week 4
New moderate-to-severe exacerbation reduction
85%; p=0.0301
COPD, compared with placebo through Week 4
Emergency visits and hospital admissions reduction
100%; p=0.0137
COPD, new exacerbations through Week 4 versus placebo
Cash, cash equivalents and short-term investments
$19.5 million
As of September 30, 2026
Net loss
$52.8 million
Nine months ended September 30, 2026, compared with $40.4 million in 2025

Previous Earnings Reports

1 past event · Latest: Aug 12
Same Type 1 event
  1. Aug 12

    Q2 earnings

    24h Move
    +9.0%

    Completed Seabreeze STAT enrollment, with September topline data and subsequent FDA Phase 3 discussions planned.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

forced expiratory volume in one second, monoclonal antibody, interleukin-4 receptor alpha, systemic corticosteroids
4 terms
forced expiratory volume in one second medical
"post-bronchodilator forced expiratory volume in one second (FEV1)"
Forced expiratory volume in one second (FEV1) is the volume of air a person can forcefully exhale in the first second after taking a full breath in, measured by spirometry. It is reported as an absolute volume (liters) and often as a percentage of a predicted value based on a person’s age, sex, height and ethnicity; clinicians use changes or percentages of predicted FEV1 to assess and quantify airflow obstruction or improvement in lung function. The measure depends on patient effort and correct testing technique, so repeatable, standardized spirometry is required for reliable results.
monoclonal antibody medical
"next-generation fully human monoclonal antibody targeting interleukin-4 receptor alpha"
A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.
interleukin-4 receptor alpha medical
"monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα)"
A cell-surface protein that binds the immune signaling molecules interleukin-4 (IL-4) and, as part of a receptor complex, interleukin-13 (IL-13), transmitting signals into the cell that change gene activity and cellular behavior. It is the alpha subunit of the IL-4 receptor complex, pairs with other receptor chains to activate intracellular pathways (notably JAK/STAT6) in immune and structural cells, and plays a central role in regulating allergic and type‑2 immune responses.
systemic corticosteroids medical
"rescue bronchodilators and systemic corticosteroids"
Systemic corticosteroids are prescription medicines that mimic natural steroid hormones and are taken by mouth or given by injection to reduce inflammation and calm the immune system throughout the whole body. They matter to investors because they can drive large prescription sales and strongly influence clinical trial outcomes, safety warnings, regulatory approvals and insurance coverage; like a master switch that eases symptoms but can cause significant side effects that affect a drug’s market value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

– Reported positive preliminary topline data from global Phase 2 Seabreeze STAT studies evaluating rademikibart as an adjunct treatment for acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD) –

– Plans to engage with the U.S. Food and Drug Administration (FDA) to gain alignment on potential Phase 3 programs for acute exacerbations of asthma in December 2026 and for COPD in the first quarter of 2027 –

SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today reported financial results for the three and nine months ended September 30, 2026, and provided a business update.

“We believe topline results from our Phase 2 Seabreeze STAT asthma and COPD studies mark a significant inflection point in the development of rademikibart as an add-on treatment to rescue bronchodilators and systemic corticosteroids for the treatment of acute exacerbations,” said Barry Quart, Pharm.D., CEO and Director of Connect Biopharma. “Across both studies, rademikibart demonstrated clinically meaningful improvements in outcomes compared to placebo during the high-risk period following an acute exacerbation. In asthma patients receiving rademikibart there was a significant improvement in pulmonary function by Day 7 that was maintained through Week 4. There were no hospitalizations or emergency department visits through Week 4 in COPD patients receiving rademikibart, which was a 100% reduction compared to placebo. We believe these findings support the potential of rademikibart to redefine how acute exacerbations are managed, addressing both the acute event and the 4-week high-risk period following an exacerbation, to improve patient outcomes and reduce the substantial economic burden on healthcare systems. We are preparing to engage with the FDA to align on potential pivotal development programs for rademikibart for the treatment of acute asthma exacerbations next month followed by COPD in the first quarter of 2027.”

Recent Highlights

Development Highlights

  • In September 2026, the Company reported preliminary topline data from the Phase 2 Seabreeze STAT asthma and COPD studies evaluating the safety and efficacy of rademikibart as an adjunct treatment for acute exacerbations. We believe results from both studies support advancement into Phase 3 development. The Company plans to meet with the FDA to gain alignment on potential Phase 3 registrational programs in asthma in December 2026 and for COPD in first quarter of 2027.
  • Key Phase 2 Seabreeze STAT Asthma study (CBP-201-206) topline results include:
    • Rademikibart demonstrated a statistically significant improvement in lung function, with patients achieving a 250 mL increase in post-bronchodilator forced expiratory volume in one second (FEV1) at Day 7 compared to 120 mL with placebo (p=0.023) that was maintained through Week 4 (p=0.012).
    • Rademikibart reduced the treatment failure rate by approximately 66% over 28 days compared to placebo (p=0.153). The endpoint missed statistical significance due to an overall lower treatment failure rate than projected. The Phase 2 studies did not have an upper limit on pulmonary function at baseline. Using the proposed entry criteria planned for the potential Phase 3 program, which includes an upper limit of <80% for baseline percent predicted FEV1, the observed reduction in treatment failure rate was 86% (p=0.0282).
    • Rademikibart demonstrated a 50% reduction in emergency department or unscheduled medical visits for worsening asthma symptoms versus placebo.
  • Key Phase 2 Seabreeze STAT COPD study (CBP-201-207) topline results include:
    • Rademikibart demonstrated significant reductions in COPD disease burden, including an 81% reduction in the rate of treatment failure (p=0.0122) and an 85% reduction in new moderate-to-severe exacerbations (p=0.0301) through Week 4 compared to placebo.
    • Rademikibart significantly reduced emergency department visits and hospital admissions for new exacerbations by 100% through Week 4 compared to placebo (p=0.0137), along with significant reductions in COPD symptoms and rescue inhaler use.
    • Rademikibart demonstrated a clinically meaningful improvement in lung function, with a 70 mL greater increase in FEV1 versus placebo at Week 4 (p=0.1607). We believe the smaller improvement in FEV1 in COPD patients was likely due to the substantially greater fixed airflow limitations and much lower responsiveness to bronchodilators in this population compared to asthma patients.
  • Rademikibart was well tolerated in both Phase 2 Seabreeze STAT asthma and COPD studies, with no new safety signals, fewer treatment emergent adverse events and fewer serious adverse events than placebo.

Financial Results for the Three and Nine Months Ended September 30, 2026

  • Cash, cash equivalents and short-term investments were $19.5 million as of September 30, 2026.
  • License and collaboration revenues relate to the license agreement with Simcere, under which Simcere has been granted exclusive rights to develop, manufacture, and commercialize rademikibart for all indications in Greater China, including mainland China, Hong Kong, Macau, and Taiwan. License and collaboration revenues for the three months ended September 30, 2026 were $0.7 million, primarily for cost reimbursements for development activities. License and collaboration revenues for the nine months ended September 30, 2026 were $3.7 million, primarily related to the achievement of a regulatory-based milestone, net of development cost sharing. License and collaboration revenues for the three and nine months ended September 30, 2025 were $16,000 and $64,000, respectively, for cost reimbursements for clinical materials. As a part of the Simcere license agreement, Connect is eligible to receive remaining milestone payments up to an aggregate amount of approximately $99 million upon the achievement of certain development, regulatory and commercial milestones. Connect is also eligible to receive royalties at tiered percentage rates up to low double-digit percentages on net sales in Greater China.
  • Research and development expense for the three and nine months ended September 30, 2026 was $12.8 million and $44.1 million, respectively, compared with $11.1 million and $26.5 million, respectively, for the same periods in 2025. The increase in research and development expense was primarily due to an increase in rademikibart-related development costs as a result of the initiation of the Phase 2 Seabreeze STAT asthma and COPD studies in May 2025.
  • General and administrative expense for the three and nine months ended September 30, 2026 was $4.3 million and $13.1 million, respectively, compared with $6.6 million and $16.1 million, respectively, for the same periods in 2025. The decrease in general and administrative expense was primarily due to a decrease in professional fees, as the prior year periods included one-time professional fees to support our efforts to become more U.S.-centric, partially offset by an increase in non-cash, share-based compensation expense.
  • Net loss for the three and nine months ended September 30, 2026 was $16.2 million, or ($0.26) per share, and $52.8 million, or ($0.87) per share, respectively, compared with $17.2 million, or ($0.31) per share, and $40.4 million, or ($0.73) per share, respectively, for the same periods in 2025.

About Rademikibart

Rademikibart is a next-generation fully human monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα), a common subunit of interleukin-4 receptor (IL-4) and interleukin-13 receptor (IL-13). The rapid onset of action was observed following the first dose of rademikibart in the Phase 2 maintenance asthma trial CBP-201-WW002, which differs from the clinical response observed with other biologics. In human cadaveric precision cut lung slices (PCLS), IL-13 reduced maximal β₂-agonist (formoterol)-induced bronchodilation by approximately 50%. Rademikibart restored approximately two-thirds of this loss, achieving maximal bronchodilation of 79% to 82%, with a consistent effect across the concentrations tested, whereas dupilumab and benralizumab produced partial and minimal recovery, respectively. We believe the unique binding of rademikibart with IL-4Rα has the potential to block the functions of IL-4 and IL-13 more effectively than first-generation products such as dupilumab, thereby potentially achieving improved treatment of T helper 2 related inflammatory diseases such as atopic dermatitis, asthma and COPD. However, head-to-head clinical studies comparing rademikibart to dupilumab, benralizumab or other products have not been conducted to date.

About Connect Biopharma

Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4Rα. The Company has completed global Phase 2 clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. Based on the positive results from the completed Phase 2 studies, the Company plans to pursue both acute and chronic administration of rademikibart for asthma and COPD. Connect has granted an exclusive license to Simcere Pharmaceutical Co., Ltd., for rademikibart in Greater China. Under the exclusive license and collaboration agreement, Connect is eligible to receive remaining milestone payments up to an aggregate amount of approximately $99 million upon the achievement of certain development, regulatory and commercial milestones. Connect is also eligible to receive royalties at tiered percentage rates up to low double-digit percentages on net sales in Greater China.

For more information visit www.connectbiopharma.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not of historical fact and include, without limitation, statements regarding future events, our cash balance and cash runway, financial guidance, future financial and operating results and related expectations, business strategy and plans, prospective products (as well as their potential to achieve a differentiated, competitive, or favorable benefit or profile or trend relative to other products or otherwise, including on safety, tolerability, improvement, maintenance, clinical response, dosing, efficacy and/or convenience), statements regarding the timing or results of any interim analysis or interim, topline or preliminary data and whether such analysis or data is indicative of safety, efficacy, final trial results or likelihood of regulatory approval for our product candidates, planned or expected meetings with the FDA or any other regulatory authorities, planned or expected product approval applications or approvals, anticipated milestones and milestone payments, expected data readouts and enrollments and the timing thereof, research and development plans and costs, potential future partnerships, expectations about existing partnerships, timing and likelihood of success, objectives of management for future operations, future results of anticipated product development efforts, adequacy of existing cash and potential partnership funding to fund operations and capital expenditure requirements, anticipated patient populations, market opportunities and potential pricing strategies for our prospective products, if approved, our plans for rademikibart, including potential indications, as well as statements regarding industry trends. These statements are based on management’s current expectations of future events only as of the date of this press release and are inherently subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among other things: our ability to continue as a going concern; our ability to regain compliance with the continued listing requirements of Nasdaq; the sufficiency of our current cash, cash equivalents and short-term investments to fund our operations; the timing and amount of actual expenses, including, without limitation, our anticipated combined U.S. GAAP R&D and G&A expenses; the ability of our clinical trials to demonstrate safety and efficacy of our product candidates and other positive results; whether we will need expanded or additional trials in order to advance rademikibart into Phase 3 development or to obtain regulatory approval for rademikibart or any of our future product candidates; the timing and outcome of any meetings with the FDA or other regulatory authorities regarding further development of our product candidates, including with respect to potential Phase 3 programs for rademikibart; whether the National Medical Products Administration (NMPA) approves Simcere’s pending New Drug Application for rademikibart for atopic dermatitis in China; our ability to obtain and maintain regulatory approval of our product candidates; existing regulations and regulatory developments in the U.S., the People’s Republic of China, Europe and other jurisdictions; our plans and ability to obtain, maintain, protect and enforce our intellectual property rights and our proprietary technologies, including extensions of existing patent terms where available; our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials; the degree of market acceptance of our product candidates, if approved, by physicians, patients, healthcare payors and others in the medical community, and the degree to which our product candidates reduce the economic burden on healthcare systems; the impact on our business of adverse global macroeconomic and geopolitical conditions, including high interest rates, the inflationary environment, recessionary fears, foreign exchange rate volatility, instability in financial institutions, government shutdowns, changes in monetary policy, changes in trade policies, including tariffs and other trade restrictions or the threat of such actions, and rising geopolitical instability, including the conflicts in Ukraine and the Middle East and the related volatility in the price of oil and other commodity prices; as well as the risks and uncertainties described in Part I, “Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2025, our subsequent Quarterly Reports on Form 10-Q and our other filings with the SEC.

Words such as “aim,” “anticipate,” “believe,” “commitments,” “continue,” “could,” “design,” “estimate,” “expect,” “feel,” “goal,” “intend,” “may,” “might,” “objective,” “optimistic,” “plan,” “potential,” “predict,” “promising,” “seek,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. The inclusion of forward-looking statements should not be regarded as a representation by Connect Biopharma that any of its expectations, projections or plans will be achieved. Actual results or outcomes, or the timing of such results or outcomes, may differ materially from those expressed or implied in our forward-looking statements due to the risks and uncertainties described above. These forward-looking statements should not be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such forward-looking statements have been made are correct or exhaustive or, in the case of the assumptions, fully stated herein. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You are cautioned not to place undue reliance on the scientific data presented or these forward-looking statements, which speak only as of the date hereof. Except as required by law, Connect Biopharma undertakes no obligation to publicly update any forward-looking statements, whether because of new information, future events or otherwise.

This press release discusses our product candidate, rademikibart, which is under clinical investigation and has not yet been approved for marketing by the FDA, the NMPA, or by any other regulatory agency. No representation is made as to the safety or effectiveness of rademikibart for the uses for which it is being studied. The trademarks included herein are the property of the owners thereof and are used for reference purposes only.

Connect Biopharma Holdings Limited
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
(unaudited)

  Three Months Ended
September 30,
 Nine Months Ended
September 30,
   2026   2025   2026   2025 
License and collaboration revenues $736  $16  $3,673  $64 
Operating expenses:        
Research and development expense  12,789   11,110   44,092   26,516 
General and administrative expense  4,259   6,583   13,104   16,096 
Total operating expenses  17,048   17,693   57,196   42,612 
Loss from operations  (16,312)  (17,677)  (53,523)  (42,548)
Total other income, net  182   538   819   2,347 
Net loss before income tax  (16,130)  (17,139)  (52,704)  (40,201)
Income tax expense  20   61   128   170 
Net loss $(16,150) $(17,200) $(52,832) $(40,371)
         
Basic and diluted net loss per ordinary share $(0.26) $(0.31) $(0.87) $(0.73)
Weighted-average ordinary shares outstanding, basic and diluted  62,974   55,716   60,825   55,523 


Connect Biopharma Holdings Limited
Condensed Consolidated Balance Sheet Data
(in thousands)
(unaudited)

  September 30, 2026
 December 31, 2025
Cash, cash equivalents and short-term investments $19,493  $44,342 
Total assets $27,770  $56,075 
Total shareholders' equity $12,055  $41,980 


Investor Relations Contact: 

Alex Lobo
Precision AQ
Alex.lobo@precisionaq.com
(212) 698-8802

Media Contact:

Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Connect Biopharma report for third-quarter 2026 earnings?

Connect reported a $16.150 million net loss, or $0.26 per share, compared with $17.200 million, or $0.31 per share, a year earlier. License and collaboration revenue increased to $736,000 from $16,000, primarily reflecting reimbursements for development activities.

What did Connect Biopharma's Phase 2 rademikibart studies show?

Preliminary Phase 2 results showed statistically significant lung-function improvement in asthma and reduced treatment failures in COPD versus placebo. The overall asthma treatment-failure endpoint missed statistical significance, as did the COPD lung-function difference. Both studies reported no new safety signals.

Why did Connect Biopharma's asthma treatment-failure endpoint miss statistical significance?

Connect attributed the missed endpoint to an overall treatment-failure rate lower than projected. The approximately 66% reduction versus placebo over 28 days had a p-value of 0.153. Among patients meeting proposed Phase 3 entry criteria, including baseline percent predicted lung function below 80%, the observed reduction was 86% (p=0.0282).

What payments could Connect Biopharma receive under its Simcere agreement?

Connect is eligible for remaining milestone payments of up to approximately $99 million, subject to development, regulatory and commercial achievements, plus tiered royalties up to low double-digit percentages on Greater China net sales. Simcere holds exclusive rights to develop, manufacture and commercialize rademikibart for all indications in mainland China, Hong Kong, Macau and Taiwan.

Why did Connect Biopharma's research and administrative expenses change in 2026?

Research expense increased primarily because of rademikibart development costs following the May 2025 initiation of the Phase 2 studies, while administrative expense declined primarily because of lower professional fees. The prior-year periods included one-time fees supporting a more U.S.-centric organization; increased non-cash share-based compensation partly offset the administrative savings.

Keep reading